Features of systemic sclerosis (scleroderma)-associated interstitial lung disease with an increased likelihood of disease progression

Disease duration <4 years

Diffuse cutaneous systemic sclerosis

Pulmonary function tests

FVC <65%

DLCO <55%

HRCT

Interstitial lung disease affecting >20% of the lung

Serology

Anti-topoisomerase I (anti-Scl-70) antibodies

FVC: forced vital capacity; DLCO: diffusing capacity for carbon monoxide; SpO₂: oxygen saturation; 6MWT: six-minute walk test; HRCT: high resolution computed tomography.

Data from:

Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. Arthritis Rheumatol 2014; 66:1625.
Moore OA, Goh N, Corte T, et al. Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology (Oxford) 2013; 52:155.

Graphic 105688 Version 3.0

خرید پکیج

Features of systemic sclerosis (scleroderma)-associated interstitial lung disease with an increased likelihood of disease progression